US Patent 11160800 Methods of treatment using a JAK inhibitor compound
Patent 11160800 was granted and assigned to Theravance on November, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+250 characters)
Article
Patent abstract
The invention relates to methods of treating ocular diseases and certain respiratory diseases using the compound 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol
Edits on 7 Jun, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 27 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
111608000
Date of Patent
November 2, 2021
0Patent Application Number
201912180
Date Filed
December 18, 2019
0Official Website
Edits on 24 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
111608000
Date of Patent
November 2, 2021
0Patent Application Number
201912180
Date Filed
December 18, 2019
0Official Website
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 9 Nov, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 11160800 Methods of treatment using a JAK inhibitor compound
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11160800
Date of patent
November 2, 2021
Patent application number
20191218
Date Filed
December 18, 2019
Find more entities like US Patent 11160800 Methods of treatment using a JAK inhibitor compound
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
